Skip to content
sellWeak10b5-1 plan

Pamela J. Cramer sold $372k of RYTM

Chief Human Resources Officer at RHYTHM PHARMACEUTICALS, INC.. 3,350 shares at an average of $111.00, traded Dec 11, 2025, filed Dec 15, 2025.

Warning score
0
Value
$372k
3,350 shares
Holdings after
20,814
-14% from before
From 52-week low
+151%
low $46.95, close $117.62
From 52-week high
0%
high $117.62, as of Dec 11, 2025

Score components

  • Role
    Officer
    +15
  • Trade size
    $372k at market
    +15
  • Share of holdings sold
    Sold 14% of holdings
    +5
  • Cluster
    No other insider selling within 14 days
    0
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

RYTMOct 9, 2026 · close 90.78
Since filing Dec 15, 2025: -19.3%SPY +15.6% · excess -34.9%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001104659-25-121181, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Dec 11, 2025MOption exercise
Common Stock10b5-1
+3,350$27.35$92k24,164Dec 15, 2025
Dec 11, 2025SOpen-market sale
Common Stock10b5-1
-3,350$111.00$372k20,814Dec 15, 2025
Dec 11, 2025MOption exercise
Stock Options (Right to Buy)derivative10b5-1
-3,350$0.00$08,375Dec 15, 2025

Related signals

Other insiders at RHYTHM PHARMACEUTICALS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
28Weak
RYTMsell 210b5-1
RHYTHM PHARMACEUTICALS, INC.
David P Meeker
President and CEO
$5.1M
50,000 shares
-17%
30Weak
RYTMsell 210b5-1
RHYTHM PHARMACEUTICALS, INC.
Hunter C Smith
Chief Financial Officer
$6.6M
62,774 shares
-36%
0Weak
RYTMsell10b5-1
RHYTHM PHARMACEUTICALS, INC.
Pamela J. Cramer
Chief Human Resources Officer
$352k
3,350 shares
-14%
33Weak
RYTMsell 210b5-1
RHYTHM PHARMACEUTICALS, INC.
Pamela J. Cramer
Chief Human Resources Officer
$2.3M
22,866 shares
-57%
33Weak
RYTMsell 210b5-1
RHYTHM PHARMACEUTICALS, INC.
Joseph Shulman
Chief Technical Officer
$1.1M
9,748 shares
-53%
7Weak
RYTMsell 210b5-1
RHYTHM PHARMACEUTICALS, INC.
Joseph Shulman
Chief Technical Officer
$324k
2,815 shares
-25%
25Weak
RYTMsell10b5-1
RHYTHM PHARMACEUTICALS, INC.
Joseph Shulman
Chief Technical Officer
$1.6M
14,437 shares
-63%
25Weak
RYTMsell10b5-1
RHYTHM PHARMACEUTICALS, INC.
Joseph Shulman
Chief Technical Officer
$1.8M
16,781 shares
-66%
21Weak
RYTMsell 310b5-1
RHYTHM PHARMACEUTICALS, INC.
Joseph Shulman
Chief Technical Officer
$419k
4,188 shares
-33%
26Weak
RYTMsell 410b5-1
RHYTHM PHARMACEUTICALS, INC.
Christopher Paul German
Corporate Controller & CAO
$143k
1,500 shares
-62%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Pamela J. Cramer sold $372k of RYTM | InsiderTell